|
1.
|
Menendez D, Inga A and Resnick MA: The
expanding universe of p53 targets. Nat Rev Cancer. 9:724–737. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
4.
|
Chan TA, Hermeking H, Lengauer C, Kinzler
KW and Vogelstein B: 14-3-3s is required to prevent mitotic
catastrophe after DNA damage. Nature. 401:616–620. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Cohen HY, Lavu S, Bitterman KJ, et al:
Acetylation of the C terminus of Ku70 by CBP and PCAF controls
Bax-mediated apoptosis. Mol Cell. 13:627–638. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Wu WS, Heinrichs S, Xu D, et al: Slug
antagonizes p53-mediated apoptosis of hematopoietic progenitors by
repressing puma. Cell. 123:641–653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Janssens S, Tinel A, Lippens S and Tschopp
J: PIDD mediates NF-kappaB activation in response to DNA damage.
Cell. 123:1079–1092. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Fang L, Li G, Liu G, Lee SW and Aaronson
SA: p53 induction of heparin-binding EGF-like growth factor
counteracts p53 growth suppression through activation of MAPK and
PI3K/Akt signaling cascades. EMBO J. 20:1931–1939. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Ongusaha PP, Kim JI, Fang L, et al: p53
induction and activation of DDR1 kinase counteract p53-mediated
apoptosis and influence p53 regulation through a positive feedback
loop. EMBO J. 22:1289–1301. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Vassilev LT, Vu BT, Graves B, et al: In
vivo activation of the p53 pathway by small-molecule antagonists of
MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kojima K, Konopleva M, McQueen T, O’Brien
S, Plunkett W and Andreeff M: Mdm2 inhibitor Nutlin-3a induces
p53-mediated apoptosis by transcription-dependent and
transcription-independent mechanisms and may overcome Atm-mediated
resistance to fludarabine in chronic lymphocytic leukemia. Blood.
108:993–1000. 2006. View Article : Google Scholar
|
|
13.
|
Vassilev LT: MDM2 inhibitors for cancer
therapy. Trends Mol Med. 13:23–31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tovar C, Rosinski J, Filipovic Z, et al:
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in
cancer: implications for therapy. Proc Natl Acad Sci USA.
103:1888–1893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Enge M, Bao W, Hedstrom E, Jackson SP,
Moumen A and Selivanova G: MDM2-dependent downregulation of p21 and
hnRNP K provides a switch between apoptosis and growth arrest
induced by pharmacologically activated p53. Cancer Cell.
15:171–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Rinaldo C, Prodosmo A, Siepi F, et al:
HIPK2 regulation by MDM2 determines tumor cell response to the
p53-reactivating drugs nutlin-3 and RITA. Cancer Res. 69:6241–6248.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lee SY, Shin SJ and Kim HS: ERK1/2
activation mediated by the nutlin3-induced mitochondrial
translocation of p53. Int J Oncol. 42:1027–1035. 2013.PubMed/NCBI
|
|
18.
|
Ryter SW, Alam J and Choi AM: Heme
oxygenase-1/carbon monoxide: from basic science to therapeutic
applications. Physiol Rev. 86:583–650. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Yang JD, Nakamura I and Roberts LR: The
tumor microenvironment in hepatocellular carcinoma: current status
and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Was H, Dulak J and Jozkowicz A: Heme
oxygenase-1 in tumor biology and therapy. Curr Drug Targets.
11:1551–1570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Berberat PO, Dambrauskas Z, Gulbinas A, et
al: Inhibition of heme oxygenase-1 increases responsiveness of
pancreatic cancer cells to anticancer treatment. Clin Cancer Res.
11:3790–3798. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Rushworth SA and MacEwan DJ: HO-1
underlies resistance of AML cells to TNF-induced apoptosis. Blood.
111:3793–3801. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Guan J, Wu X, Arons E and Christou H: The
p38 mitogen-activated protein kinase pathway is involved in the
regulation of heme oxygenase-1 by acidic extracellular pH in aortic
smooth muscle cells. J Cell Biochem. 105:1298–1306. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Alam J and Cook JL: How many transcription
factors does it take to turn on the heme oxygenase-1 gene? Am J
Respir Cell Mol Biol. 36:166–174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nam SY and Sabapathy K: p53 promotes
cellular survival in a context-dependent manner by directly
inducing the expression of haeme-oxygenase-1. Oncogene.
30:4476–4486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Jang JY, Kim MK, Jeon YK, Joung YK, Park
KD and Kim CW: Adenovirus adenine nucleotide translocator-2 shRNA
effectively induces apoptosis and enhances chemosensitivity by the
down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol
Med. 44:251–259. 2012. View Article : Google Scholar
|
|
28.
|
Lau LM, Nugent JK, Zhao X and Irwin MS:
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73
function. Oncogene. 27:997–1003. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Zhao Y, Chaiswing L, Velez JM, et al: p53
translocation to mitochondria precedes its nuclear translocation
and targets mitochondrial oxidative defense protein-manganese
superoxide dismutase. Cancer Res. 65:3745–3750. 2005. View Article : Google Scholar
|
|
30.
|
Mihara M, Erster S, Zaika A, et al: p53
has a direct apoptogenic role at the mitochondria. Mol Cell.
11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Palacios G, Crawford HC, Vaseva A and Moll
UM: Mitochondrially targeted wild-type p53 induces apoptosis in a
solid human tumor xenograft model. Cell Cycle. 7:2584–2590. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Leu JI, Dumont P, Hafey M, Murphy ME and
George DL: Mitochondrial p53 activates Bak and causes disruption of
a Bak-Mcl1 complex. Nat Cell Biol. 6:443–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Vaseva AV, Marchenko ND, Ji K, Tsirka SE,
Holzmann S and Moll UM: p53 opens the mitochondrial permeability
transition pore to trigger necrosis. Cell. 149:1536–1548. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Vaseva AV, Marchenko ND and Moll UM: The
transcription-independent mitochondrial p53 program is a major
contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle.
8:1711–1719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Essmann F, Pohlmann S, Gillissen B, Daniel
PT, Schulze-Osthoff K and Janicke RU: Irradiation-induced
trans-location of p53 to mitochondria in the absence of apoptosis.
J Biol Chem. 280:37169–37177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Moreno CS, Matyunina L, Dickerson EB, et
al: Evidence that p53-mediated cell-cycle-arrest inhibits
chemotherapeutic treatment of ovarian carcinomas. PLoS One.
2:e4412007. View Article : Google Scholar : PubMed/NCBI
|
